胶质母细胞瘤治疗现状和困境  

Current state and dilemma of glioblastoma treatment

作　　者：刘泓渊 曾辉 李宗平[1] 周良学 LIU Hongyuan;ZENG Hui;LI Zongping;ZHOU Liangxue(Department of Neurosurgery,Mianyang Central Hospital,Affiliated Mianyang Hospital,University of Electronic Science and Tech-nology,Mianyang 621000,China;Department of Neurosurgery,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]绵阳市中心医院,电子科技大学附属绵阳医院神经外科,绵阳621000 [2]四川大学华西医院神经外科,成都610041

出　　处：《西南医科大学学报》2024年第4期283-288,共6页Journal of Southwest Medical University

基　　金：国家自然科学基金(81772693);科技部“十三五”“重大新药创制”国家科技重大专项(2019ZX09301-147)。

摘　　要：胶质母细胞瘤(glioblastoma,GBM)是颅内最常见的原发性恶性肿瘤,治疗困难,预后极差。GBM患者目前一般采用包括手术、放疗和化疗的综合治疗方案,中位生存期仅14.6个月,GBM复发患者中位生存期不超过8个月。新的治疗手段,如靶向治疗、电场治疗、溶瘤病毒、细胞治疗、肿瘤疫苗等不断涌现,在一定程度上延长了GBM患者生存期。但由于肿瘤恶性程度高、异质性高、免疫抑制性微环境、对现有放化疗响应差等原因,治疗效果尚未达到预期。本文对GBM传统治疗和新兴治疗手段进行分析及评述,解析其优点与不足,以期为GBM的治疗方案选择、设计,以及新药、新策略、新仪器设备研发等提供参考和思路。Glioblastoma(GBM)is the most common primary intracranial malignant tumor,standing with treatment prospective and poor prognosis.GBM is treated with a comprehensive treatment regimen including surgery,radiotherapy,and chemotherapy.The me-dian survival for GBM is only 14.6 months,and for recurrence,it is no more than 8 months.New therapies such as targeted therapy,elec-tric field therapy,oncolytic viruses,cell therapy,and tumor vaccines are emerging,which prolong the survival of GBM.Due to the high degree of malignancy,high degree of heterogeneity,immunosuppressive microenvironment,poor response to radiotherapy and chemo-therapy,the therapeutic effect has not met the expectation.This article analyzed and reviewed the traditional and emerging treatments for GBM,and analyzed their advantages and disadvantages,in order to provide references and ideas for GBM treatment program selec-tion and design,as well as new drugs,new strategies,new instruments and equipments.

关 键 词：胶质母细胞瘤 手术 放疗 化疗 免疫治疗 肿瘤微环境 

分 类 号：R739.4[医药卫生—肿瘤]